泰达生物2026年上半年营收2.96亿元,经调整净利润1,020.83万元

公告速递
Sep 24

2026年上半年,泰达生物(股票代码:08189)实现营收2.96亿元,同比增长30.75%。经调整净利润1,020.83万元,相较2025年同期净亏损642.64万元,由亏转盈。报告期内综合毛利3,336.26万元,同比增长141.40%,综合毛利率由上年同期的6.10%上升至11.27%。

公司在费用管控方面持续优化,销售及分销成本320.45万元,同比下降19.09%;研发及行政开支1,317.72万元,同比下降20.39%。经营现金流方面由2025年同期净流出9,839.76万元转为本期净流入3,749.56万元。

公司目前主要聚焦于两大业务领域:一是肥料产品业务,报告期内实现收入1.90亿元;二是AI健康养老产品及服务业务,实现收入1.06亿元。第二大板块在报告期内贡献了可观的增量,驱动整体业绩与盈利水平显著提升。公司表示将继续推进AI技术与医疗健康、养老服务等领域的深度融合,进一步释放全栈AI医疗与公共数据运维平台的业务潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10